Valion Bio, Inc. Increase (Decrease) in Accounts Payable, Trade
Valion Bio, Inc. (VBIO) reported Increase (Decrease) in Accounts Payable, Trade of $109.00 thousand for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2025-08-14
- Valion Bio, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2025-06-30 was -$204.00K.
- Valion Bio, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2025-03-31 was $313.00K.
- Valion Bio, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2024-12-31 was -$208.00K, a 377.33% decline year-over-year.
- Valion Bio, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2024-09-30 was -$113.00K.
- Valion Bio, Inc. increase (decrease) in accounts payable, trade for fiscal 2024 was -$588.00K.
- Valion Bio, Inc. increase (decrease) in accounts payable, trade for fiscal 2023 was -$610.00K, a 214.23% decline from fiscal 2022.
- Valion Bio, Inc. increase (decrease) in accounts payable, trade for fiscal 2022 was $534.00K, a 27.45% increase from fiscal 2021.
- Valion Bio, Inc. increase (decrease) in accounts payable, trade for fiscal 2021 was $419.00K.
| Period end | Increase (Decrease) in Accounts Payable, Trade 1 month | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month |
|---|---|---|---|---|---|
| 2025-06-30 | -$204.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $109.00K 10-Q · filed 2025-08-14 | -$99.00K derived: sum of 3 quarters · filed 2025-08-14 | -$212.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2025-03-31 | $313.00K 10-Q · filed 2025-05-15 | $105.00K derived: sum of 2 quarters · filed 2025-05-15 | -$8.00K derived: sum of 3 quarters · filed 2025-05-15 | -$109.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-12-31 | -$208.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -$321.00K derived: sum of 2 quarters · filed 2025-03-21 | -$422.00K derived: sum of 3 quarters · filed 2025-08-14 | -$588.00K 10-K · filed 2025-03-21 | |
| 2024-09-30 | -$113.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$214.00K derived: sum of 2 quarters · filed 2025-08-14 | -$380.00K 10-Q · filed 2024-11-14 | -$305.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-06-30 | -$101.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$267.00K 10-Q · filed 2025-08-14 | -$192.00K derived: sum of 3 quarters · filed 2025-08-14 | -$385.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$166.00K 10-Q · filed 2025-05-15 | -$91.00K derived: sum of 2 quarters · filed 2025-05-15 | -$284.00K derived: sum of 3 quarters · filed 2025-05-15 | -$547.00K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -$118.00K derived: sum of 2 quarters · filed 2025-03-21 | -$381.00K derived: sum of 3 quarters · filed 2025-03-21 | -$610.00K 10-K · filed 2025-03-21 | |
| 2023-09-30 | -$193.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$456.00K derived: sum of 2 quarters · filed 2024-11-14 | -$685.00K 10-Q · filed 2024-11-14 | -$964.00K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$263.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$492.00K 10-Q · filed 2024-08-14 | -$771.00K derived: sum of 3 quarters · filed 2024-08-14 | -$1.08M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$229.00K 10-Q · filed 2024-05-15 | -$508.00K derived: sum of 2 quarters · filed 2024-05-15 | -$821.00K derived: sum of 3 quarters · filed 2024-05-15 | $468.00K derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$279.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$592.00K derived: sum of 2 quarters · filed 2024-03-25 | $697.00K derived: sum of 3 quarters · filed 2024-03-25 | $534.00K 10-K · filed 2024-03-25 | |
| 2022-09-30 | -$313.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $976.00K derived: sum of 2 quarters · filed 2023-11-14 | $813.00K 10-Q · filed 2023-11-14 | $303.00K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.13M 10-Q · filed 2023-08-14 | $616.00K derived: sum of 3 quarters · filed 2023-08-14 | $731.00K derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$163.00K 10-Q · filed 2023-05-15 | -$673.00K derived: sum of 2 quarters · filed 2023-05-15 | -$558.00K derived: sum of 3 quarters · filed 2023-05-15 | -$39.00K derived: sum of 4 quarters · filed 2023-05-15 | |
| 2022-01-31 | -$163.00K 10-Q · filed 2022-05-16 | ||||
| 2021-12-31 | -$510.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$395.00K derived: sum of 2 quarters · filed 2023-03-31 | $124.00K derived: sum of 3 quarters · filed 2023-03-31 | $419.00K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $115.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $634.00K derived: sum of 2 quarters · filed 2022-11-14 | $929.00K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $519.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $814.00K 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $295.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |